Patents by Inventor Oren PARNAS

Oren PARNAS has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Assays for massively combinatorial perturbation profiling and cellular circuit reconstruction
    Patent number: 11214797
    Abstract: The present invention provides tools and methods for the systematic analysis of genetic interactions, including higher order interactions. The present invention provides tools and methods for combinatorial probing of cellular circuits, for dissecting cellular circuitry, for delineating molecular pathways, and/or for identifying relevant targets for therapeutics development.
    Type: Grant
    Filed: April 27, 2018
    Date of Patent: January 4, 2022
    Assignees: The Broad Institute, Inc., Massachusetts Institute of Technology, The Regents of the University of California
    Inventors: Aviv Regev, Brittany Adamson, Brian Cleary, Le Cong, Atray Dixit, Jellert Gaublomme, Eric S. Lander, Thomas Norman, Oren Parnas, Orit Rozenblatt-Rosen, Alexander K. Shalek, Jonathan Weissman
  • Delivery, use and therapeutic applications of the CRISPR-cas systems and compositions for modeling mutations in leukocytes
    Patent number: 11197467
    Abstract: The invention involves a method for modulating leukocyte activity, comprising delivering to a leukocyte a vector containing nucleic acid molecule(s), whereby the leukocyte contains Cas9 and the vector expresses one or more RNAs to guide the Cas9 to introduce mutations in one or more target genetic loci in the leukocyte, thereby modulating expression of one or more genes expressed in the leukocyte. The invention also involves identifying genes associated with leukocyte responses and experimental modeling of aberrant leukocyte activation and diseases associated with leukocytes by introducing mutations into leukocytes. The invention comprehends testing putative treatments with such models, e.g., testing putative chemical compounds that may be pharmaceutically relevant for treatment or gene therapy that may be relevant for treatment, or combinations thereof. The invention allows for the study of genetic diseases and putative treatments to better understand and alleviate leukocyte associated diseases.
    Type: Grant
    Filed: March 24, 2017
    Date of Patent: December 14, 2021
    Assignees: The Broad Institute, Inc., Massachusetts Institute of Technology, The General Hospital Corporation
    Inventors: Aviv Regev, Oren Parnas, Marko Jovanovic, Nir Hacohen, Thomas Eisenhaure
  • ASSAYS FOR MASSIVELY COMBINATORIAL PERTURBATION PROFILING AND CELLULAR CIRCUIT RECONSTRUCTION
    Publication number: 20190085324
    Abstract: The present invention provides tools and methods for the systematic analysis of genetic interactions, including higher order interactions. The present invention provides tools and methods for combinatorial probing of cellular circuits, for dissecting cellular circuitry, for delineating molecular pathways, and/or for identifying relevant targets for therapeutics development.
    Type: Application
    Filed: April 27, 2018
    Publication date: March 21, 2019
    Inventors: Aviv Regev, Brittany Adamson, Brian Cleary, Le Cong, Atray Dixit, Jellert Gaublomme, Eric S. Lander, Thomas Norman, Oren Parnas, Orit Rozenblatt-Rosen, Alexander K. Shalek, Jonathan Weissman
  • DELIVERY, USE AND THERAPEUTIC APPLICATIONS OF THE CRISPR-CAS SYSTEMS AND COMPOSITIONS FOR MODELING MUTATIONS IN LEUKOCYTES
    Publication number: 20180255751
    Abstract: The invention involves a method for modulating leukocyte activity, comprising delivering to a leukocyte a vector containing nucleic acid molecule(s), whereby the leukocyte contains Cas9 and the vector expresses one or more RNAs to guide the Cas9 to introduce mutations in one or more target genetic loci in the leukocyte, thereby modulating expression of one or more genes expressed in the leukocyte. The invention also involves identifying genes associated with leukocyte responses and experimental modeling of aberrant leukocyte activation and diseases associated with leukocytes by introducing mutations into leukocytes. The invention comprehends testing putative treatments with such models, e.g., testing putative chemical compounds that may be pharmaceutically relevant for treatment or gene therapy that may be relevant for treatment, or combinations thereof. The invention allows for the study of genetic diseases and putative treatments to better understand and alleviate leukocyte associated diseases.
    Type: Application
    Filed: March 24, 2017
    Publication date: September 13, 2018
    Inventors: Aviv Regev, Oren PARNAS, Marko JOVANOVIC, Nir HACOHEN, Thomas EISENHAURE